Biomarin Inventory Turnover vs Operating Margin Analysis
BMRN Stock | USD 90.87 0.64 0.70% |
Biomarin Pharmaceutical financial indicator trend analysis is way more than just evaluating Biomarin Pharmaceutical prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Biomarin Pharmaceutical is a good investment. Please check the relationship between Biomarin Pharmaceutical Inventory Turnover and its Operating Profit Margin accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Biomarin Pharmaceutical. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. To learn how to invest in Biomarin Stock, please use our How to Invest in Biomarin Pharmaceutical guide.
Inventory Turnover vs Operating Profit Margin
Inventory Turnover vs Operating Margin Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Biomarin Pharmaceutical Inventory Turnover account and Operating Margin. At this time, the significance of the direction appears to have totally related.
The correlation between Biomarin Pharmaceutical's Inventory Turnover and Operating Margin is 1.0. Overlapping area represents the amount of variation of Inventory Turnover that can explain the historical movement of Operating Margin in the same time period over historical financial statements of Biomarin Pharmaceutical, assuming nothing else is changed. The correlation between historical values of Biomarin Pharmaceutical's Inventory Turnover and Operating Margin is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Inventory Turnover of Biomarin Pharmaceutical are associated (or correlated) with its Operating Margin. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Operating Margin has no effect on the direction of Inventory Turnover i.e., Biomarin Pharmaceutical's Inventory Turnover and Operating Margin go up and down completely randomly.
Correlation Coefficient | 1.0 |
Relationship Direction | Positive |
Relationship Strength | Very Strong |
Inventory Turnover
A ratio showing how many times a company's inventory is sold and replaced over a period, indicating the efficiency of inventory management.Operating Profit Margin
Most indicators from Biomarin Pharmaceutical's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Biomarin Pharmaceutical current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Biomarin Pharmaceutical. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. To learn how to invest in Biomarin Stock, please use our How to Invest in Biomarin Pharmaceutical guide.At this time, Biomarin Pharmaceutical's Tax Provision is very stable compared to the past year. As of the 17th of April 2024, Enterprise Value Over EBITDA is likely to grow to 74.10, while Selling General Administrative is likely to drop about 246.1 M.
2021 | 2022 | 2023 | 2024 (projected) | Gross Profit | 1.4B | 1.6B | 1.8B | 1.9B | Total Revenue | 1.8B | 2.1B | 2.4B | 2.5B |
Biomarin Pharmaceutical fundamental ratios Correlations
Click cells to compare fundamentals
Biomarin Pharmaceutical Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Biomarin Pharmaceutical fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 4.7B | 5.8B | 6.0B | 6.4B | 6.8B | 7.2B | |
Short Long Term Debt Total | 848.1M | 1.1B | 1.1B | 1.1B | 1.1B | 1.2B | |
Other Current Liab | (13.0M) | 289.2M | 329.4M | 346.6M | 354.2M | 372.0M | |
Total Current Liabilities | 932.5M | 492.5M | 539.8M | 588.9M | 1.2B | 1.2B | |
Total Stockholder Equity | 3.1B | 4.1B | 4.3B | 4.6B | 5.0B | 5.2B | |
Property Plant And Equipment Net | 1.0B | 1.0B | 1.0B | 1.1B | 1.1B | 1.2B | |
Net Debt | 410.7M | 426.0M | 491.8M | 358.5M | 378.7M | 216.1M | |
Retained Earnings | (1.7B) | (861.6M) | (925.7M) | (789.2M) | (621.6M) | (652.6M) | |
Accounts Payable | 570.6M | 191.4M | 193.0M | 231.2M | 315.5M | 331.3M | |
Cash | 437.4M | 649.2M | 587.3M | 724.5M | 755.1M | 792.9M | |
Non Current Assets Total | 2.7B | 3.5B | 3.7B | 3.6B | 3.9B | 4.1B | |
Non Currrent Assets Other | 122.0M | 142.2M | 151.8M | 176.2M | 121.2M | 72.7M | |
Cash And Short Term Investments | 753.8M | 1.1B | 1.0B | 1.3B | 1.1B | 595.1M | |
Net Receivables | 377.4M | 448.4M | 373.4M | 461.3M | 633.7M | 665.4M | |
Common Stock Shares Outstanding | 179.0M | 191.7M | 182.9M | 189.0M | 191.6M | 127.6M | |
Liabilities And Stockholders Equity | 4.7B | 5.8B | 6.0B | 6.4B | 6.8B | 7.2B | |
Non Current Liabilities Total | 635.2M | 1.2B | 1.2B | 1.2B | 713.0M | 586.6M | |
Inventory | 680.3M | 698.5M | 776.7M | 894.1M | 1.1B | 1.2B | |
Other Current Assets | 130.7M | 129.9M | 110.4M | 104.5M | 141.4M | 148.5M | |
Other Stockholder Equity | 4.8B | 5.0B | 5.2B | 5.4B | 5.6B | 5.9B | |
Total Liab | 1.6B | 1.7B | 1.7B | 1.8B | 1.9B | 2.0B | |
Property Plant And Equipment Gross | 1.0B | 1.0B | 1.8B | 1.9B | 1.9B | 2.0B | |
Total Current Assets | 1.9B | 2.3B | 2.3B | 2.8B | 3.0B | 3.1B | |
Accumulated Other Comprehensive Income | 20.2M | (16.1M) | 14.4M | (3.9M) | (38.6M) | (36.7M) | |
Intangible Assets | 456.6M | 417.3M | 388.7M | 338.6M | 294.7M | 244.4M | |
Common Stock Total Equity | 178K | 180K | 182K | 184K | 211.6K | 126.8K | |
Short Term Investments | 316.4M | 416.2M | 426.6M | 567.0M | 318.7M | 276.3M | |
Common Stock | 180K | 182K | 184K | 186K | 189K | 133.2K | |
Other Assets | 612.0M | 1.6B | 1.6B | 1.6B | 1.8B | 1.9B | |
Long Term Debt | 486.2M | 1.1B | 1.1B | 1.1B | 593.1M | 553.3M | |
Property Plant Equipment | 1.0B | 1.0B | 1.0B | 1.1B | 1.3B | 1.3B | |
Other Liab | 98.1M | 174.3M | 113.7M | 73.5M | 84.5M | 81.8M | |
Net Tangible Assets | 2.5B | 3.5B | 3.7B | 4.1B | 4.7B | 4.9B | |
Retained Earnings Total Equity | (1.7B) | (1.7B) | (861.6M) | (925.7M) | (833.1M) | (874.8M) | |
Long Term Debt Total | 830.4M | 486.2M | 1.1B | 1.1B | 1.2B | 730.7M | |
Capital Surpluse | 4.7B | 4.8B | 5.0B | 5.2B | 6.0B | 3.7B | |
Long Term Investments | 412.0M | 285.5M | 507.8M | 333.8M | 611.1M | 353.3M |
Pair Trading with Biomarin Pharmaceutical
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Biomarin Pharmaceutical position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Biomarin Pharmaceutical will appreciate offsetting losses from the drop in the long position's value.Moving against Biomarin Stock
0.8 | NVO | Novo Nordisk AS Financial Report 2nd of May 2024 | PairCorr |
0.76 | ABBV | AbbVie Inc Financial Report 25th of April 2024 | PairCorr |
0.55 | EWTX | Edgewise Therapeutics Financial Report 9th of May 2024 | PairCorr |
0.55 | HOWL | Werewolf Therapeutics Financial Report 9th of May 2024 | PairCorr |
0.53 | CCCC | C4 TherapeuticsInc Financial Report 2nd of May 2024 | PairCorr |
The ability to find closely correlated positions to Biomarin Pharmaceutical could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Biomarin Pharmaceutical when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Biomarin Pharmaceutical - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Biomarin Pharmaceutical to buy it.
The correlation of Biomarin Pharmaceutical is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Biomarin Pharmaceutical moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Biomarin Pharmaceutical moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Biomarin Pharmaceutical can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Biomarin Pharmaceutical. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. To learn how to invest in Biomarin Stock, please use our How to Invest in Biomarin Pharmaceutical guide.You can also try the Balance Of Power module to check stock momentum by analyzing Balance Of Power indicator and other technical ratios.
Complementary Tools for Biomarin Stock analysis
When running Biomarin Pharmaceutical's price analysis, check to measure Biomarin Pharmaceutical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Biomarin Pharmaceutical is operating at the current time. Most of Biomarin Pharmaceutical's value examination focuses on studying past and present price action to predict the probability of Biomarin Pharmaceutical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Biomarin Pharmaceutical's price. Additionally, you may evaluate how the addition of Biomarin Pharmaceutical to your portfolios can decrease your overall portfolio volatility.
Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
Money Managers Screen money managers from public funds and ETFs managed around the world | |
Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
Stocks Directory Find actively traded stocks across global markets | |
Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities |
Is Biomarin Pharmaceutical's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Biomarin Pharmaceutical. If investors know Biomarin will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Biomarin Pharmaceutical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.98 | Earnings Share 0.87 | Revenue Per Share 12.88 | Quarterly Revenue Growth 0.202 | Return On Assets 0.0163 |
The market value of Biomarin Pharmaceutical is measured differently than its book value, which is the value of Biomarin that is recorded on the company's balance sheet. Investors also form their own opinion of Biomarin Pharmaceutical's value that differs from its market value or its book value, called intrinsic value, which is Biomarin Pharmaceutical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Biomarin Pharmaceutical's market value can be influenced by many factors that don't directly affect Biomarin Pharmaceutical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Biomarin Pharmaceutical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Biomarin Pharmaceutical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Biomarin Pharmaceutical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.